Epidermal Transglutaminase Deposits in Perilesional and Uninvolved Skin in Patients with Dermatitis Herpetiformis  by Donaldson, Matthew R. et al.
1University of Virginia, Charlottesville,
Virginia, USA and 2Instituto de Biotechnolgia,
UNAM, Cuernavaca, Mexico.
E-mail: jwf8x@virginia.edu
REFERENCES
Gomez-Munoz A (2004) Ceramide-1-phosphate:
a novel regulator of cell activation. FEBS Lett
562:5–10
Lee S, Lynch KR (2005) Brown recluse spider
(Loxosceles reclusa) venom phospholipase D
(PLD) generates lysophosphatidic acid (LPA).
Biochem J 391:317–23
Pettus BJ, Bielawska A, Spiegel S, Roddy P,
Hannun YA, Chalfant CE (2003) Ceramide
kinase mediates cytokine- and calcium iono-
phore-induced arachidonic acid release. J
Biol Chem 278:38206–13
Pettus BJ, Bielawska A, Subramanian P, Wije-
singhe DS, Maceyka M, Leslie CC et al.
(2004) Ceramide 1-phosphate is a direct
activator of cytosolic phospholipase A2. J
Biol Chem 27:11320–6
van Meeteren LA, Frederiks F, Giepmans BN,
Pedrosa MF, Billington SJ, Jost BH et al. (2004)
Sphingomyelinases D target cellular lysopho-
sphatidic acid receptors by hydrolyzing lyso-
phosphatidylcholine. J Biol Chem 27:10833–6
Epidermal Transglutaminase Deposits in Perilesional and
Uninvolved Skin in Patients with Dermatitis Herpetiformis
Journal of Investigative Dermatology (2007) 127, 1268–1271. doi:10.1038/sj.jid.5700682; published online 4 January 2007
TO THE EDITOR
Dermatitis herpetiformis (DH) is a dis-
ease precipitated by ingestion of gluten
and characterized by IgA deposits in the
dermal papillae (Nicolas et al., 2003).
Like celiac disease, DH is one presen-
tation of gluten-sensitive enteropathy
(Zone, 2005). In susceptible indivi-
duals, ingestion of gluten leads to
elaboration of antibodies against glia-
din and transglutaminase 2 (TG2) (Ox-
entenko and Murray, 2003; Alaedini
and Green, 2005; Zone, 2005). TG2,
one of nine homologous transglutami-
nases, is an autoantigen in celiac
disease (Dieterich et al., 1997; Lorand
and Graham, 2003). Serum antibodies
against TG2 can be sensitive and
specific for DH as well as celiac disease
(Dieterich et al., 1999).
Sardy et al. (2002) hypothesized that
an autoantigen related to TG2 could
explain the presentation of DH and
reported that epidermal transglutami-
nase (TG3) deposits with IgA in perile-
sional biopsies in patients with DH. IgA
deposits can occur in regions that are
not clinically involved (Fry et al., 1978;
Zone et al., 1996). To confirm the
involvement of TG3 in DH and to
determine whether TG3 deposits are
restricted to perilesional skin, we have
raised a new goat antibody against
human TG3.
In a series of nine DH patients with
active disease, we compared direct
immunofluorescence (DIF) for IgA and
TG3 in perilesional and uninvolved
skin. We also compared serology for
TG2 and TG3 and results from DIF for
IgA and TG3 in the context of a gluten-
free diet (GFD). The protocol was
approved by our Institutional Review
Board, patients consented in writing,
and we adhered to the Declaration of
Helsinki Principles. All patients had a
diagnosis of DH established by skin
biopsy showing granular IgA and had
active disease. Adherence to GFD was
reported by patients as strict or poor.
Serum was analyzed for IgA antibo-
dies against TG2, TG3, and endomy-
sium endomysial antibody (EMA).
Semiquantitative detection of anti-TG2
and -TG3 were performed using ELISA
(INOVA Diagnostics, San Diego, CA,
and Immunodiagnostik AG, Bensheim,
Germany). EMA were detected using
indirect immunofluorescence on mon-
key esophagus (University of California
at Davis) (Unsworth, 1996). Patient age,
sex, family history, adherence to GFD,
dapsone use, and serologies for anti-
bodies against TG2, TG3, and endomy-
sium are represented in Table 1. Five
patients reported strict adherence to a
GFD. Among patients adhering to a
strict GFD, four of five (80%) were
negative by IgA ELISA for anti-TG2
antibodies and EMA. All four patients
reporting poor GFD adherence had anti-
TG2 antibodies and two of four were
positive by EMA. All five patients in the
strict GFD group were seronegative for
anti-TG3 antibodies and all four patients
in the poor GFD group were positive.
The two patients with negative EMA had
the lowest values for anti-TG2.
Polyclonal TG3 antibody
Purified TG3 expressed from a baculo-
virus system was used to produce
polyclonal antibodies in goats (Ahvazi
and Steinert, 2003). Purified TG3 was a
kind gift from Dr Bijan Ahazi. To
confirm reactivity and specificity, Wes-
tern blots were performed using the
baculovirus-produced TG3 as well as
separately cloned TG2 and TG3. Com-
plementary DNAs for TG3 and TG2
were isolated by RT-PCR from human
keratinocytes using primers published
by Sardy et al., and were sequence
confirmed. Complementary DNA was
cloned in the Invitrogen pSecTag2/
Hygro B vector, lysates were purified
using a Ni2þ column (Invitrogen,
Carlsbad, CA, USA), electrophoresed,
and transferred to nitrocellulose blots.
IgG was prepared using a Protein G
column. Western blots confirmed a
high titer against both TG3 clones.
Specificity was demonstrated by lack
of reactivity against non-transfected
human embryonic kidney lysate, re-
combinant TG2 (Figure 1), and serum
and secretory (colostral) IgA (not
shown). Further specificity was estab-
lished by lack of reactivity on IIF when
reacted with skin from three patients
with linear IgA bullous dermatosis
(Figure 2e and f), two with Henoch–-
Abbreviations: DIF, direct immunofluorescence; DH, dermatitis herpetiformis; EMA, endomysial
antibody; GFD, gluten-free diet; TG2, transglutaminase 2 or tissue transglutaminase; TG3,
transglutaminase 3 or epidermal transglutaminase
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Sho¨nlein purpura and human tonsil (not
shown).
DIF
Sites of biopsy were chosen as non-
erythematous skin adjacent to lesions
(perilesional) and uninvolved skin 5 cm
away. Four sections of each biopsy
specimen were incubated with sheep
anti-IgA FITC (1:40), goat IgG anti-TG3
(1:50), or preimmune goat IgG (1:50)
for 30–60 minutes and washed. Anti-
TG3 and preimmune control slides
were incubated with FITC swine anti-
goat IgG antibody (1:100) for 30 min-
utes before washing again. A single-
blinded observer (J.J.Z.) graded all
specimens by a semiquantitative scale
(0–3þ ) (Zone et al., 1996). Table 2
shows semiquantitative immunofluor-
escence values assigned to specimens
from each of the nine patients. Typical
staining patterns are shown in Figure
1a–d. All patients had granular deposits
of IgA in the dermal papillae. Eight of
nine had overlapping deposits of TG3.
Only one specimen revealed IgA and
TG3 deposition in vessel walls in the
papillary dermis. TG3 showed staining
of variable intensity of the upper layers
of the epidermis, shown in Figure 1d.
No IgA or TG3were seen in any speci-
men within the stratum basale.
IgA DIF was more intense than TG3
in 13 of 18 specimens and equivalent in
the remaining five. IgA and TG3 DIF
were greater with poor GFD adherence.
The only patient negative for TG3 was
on a strict GFD and had sparse IgA
in perilesional skin only. All five
specimens from control subjects were
negative for IgA and TG3 immunofluor-
escence, and the three LABD and two
HSP patients were positive for IgA but
negative for TG3.
Patients with DH have TG3 in the
papillary dermis overlapping with the
deposits of IgA. Using a new antibody
raised in goat with specificity con-
firmed using a separately cloned re-
combinant protein, we have confirmed
findings of Sardy et al. suggesting TG3
is the autoantigen of DH. We also
found TG3 deposits in uninvolved skin
at least 5 cm away from lesions suggest-
ing that factors beyond these complexes
are necessary for DH eruptions.
IgA deposits were seen in all speci-
mens where TG3 was found, suggesting
TG3 is bound by autoantibodies as the
mechanism of deposition. TG3 was not
been found in the dermis in the absence
of IgA. The intensity of IgA by DIF
roughly correlated with the intensity of
staining for TG3.
As TG3 is strongly expressed in the
upper epidermis (Sardy et al., 2002), it
is reasonable to suspect that in regions
of trauma, it may be released from the
epidermal keratinocytes and diffuse
through the basement membrane. Cir-
culating autoantibodies could then bind
this antigen and form characteristic
deposits. An alternate explanation in-
volves circulating immune complexes
that deposit at the dermoepidermal
junction (Sardy et al., 2002; Preisz
et al., 2005), although we saw only
one such involved vessel. Prior reports
demonstrated IgA nephropathy in DH
patients (Helin et al., 1983; Reunala
et al., 1983). Although circulating
complexes could cause this pattern,
such deposits could also result from a
reaction against kidney TG3 (Sardy
et al., 2002).
Reported sensitivity of anti-TG2 ELI-
SA and EMA for DH has varied (Chor-
Table 1. Patient characteristics and serology
Patient Sex Age FHx GFD 1Dapsone
Anti TG2-
IgA units
IgA-EMA,
titer
IgA anti-
TG3
DH1 M 61 No Strict No 6 0 6
DH2 F 28 No Strict No 6 0 5
DH3 F 54 Yes Strict 100 mg 7 0 5
DH4 M 29 No Strict 200 mg 11 0 3
DH5 M 72 Yes Strict 25 mg 67 1:80 14
DH6 M 82 Yes Poor No 25 0 37
DH7 M 61 No Poor 25 mg 36 0 20
DH8 F 54 Yes Poor 200 mg 122 1:1280 20
DH9 M 66 No Poor No 4192 1:1280 42
EMA, endomysial antibody; F, female; GFD, gluten-free diet; M, male.
1All patients taking dapsone stopped medication for 48–72 hours before biopsy and evaluation.
1 2 3 4 5 6
−110 kDa
− 76 kDa
− 49 kDa
− 35.6 kDa
− 29 kDa
− 21.1 kDa
Figure 1. Coomassie-stained polyacrylamide gel (lanes 1–2) and Western Immunoblot (lanes 3–6)
demonstrating reactivity of goat antisera with TG3. Baculovirus produced TG3 from the NIH and TG3
expressed in human embryonic kidney cells and eluted from a denaturing column were used as substrate
and 300 ng loaded as follows: (1) NIH TG3, (2) human embryonic kidney TG3, (3) NIH TG3, (4) human
embryonic kidney TG3, (5) NIH TG3, and (6) human embryonic kidney TG3. Lanes 3 and 4 are stained
with an IgG-fraction of goat anti-TG3 at 1:300 and lanes 5 and 6 are stained with preimmune goat sera
(IgG-fraction).
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zelski et al., 1986; Reunala et al., 1987;
Volta et al., 1992; Koop et al., 2000;
Sardy et al., 2000). Studies correlate
positive serology with more severe
intestinal damage (Volta et al., 1992)
and seronegativity with adherence to
GFD (Peters and McEvoy, 1989; Volta
et al., 1992). Serology by IgA ELISA for
anti-TG3 and TG2 antibodies corre-
lated with adherence to GFD. Interest-
ingly, EMA did not correlate tightly with
TG3 or TG2 (Table 1). Mean DIF was
greater for IgA and TG3 in patients
seropositive for anti-TG2 and TG3
antibodies and reporting poor adher-
ence to GFD, but a definitive relation-
ship between serology and immune
complex deposition cannot be estab-
lished from this small patient series.
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TO THE EDITOR
The pathophysiological features of
chronic inflammatory skin diseases
such as allergic contact dermatitis and
atopic dermatitis are characterized by
the infiltration of a large number of
inflammatory cells, particularly Th2
lymphocytes (producing IL-13 and/or
IL-4 in acute lesions) and Th1 lympho-
cytes (producing IFN-g in chronic
lesions) (Leung et al., 2004). The pre-
sence of IL-13-positive cells in acute
lesions of atopic dermatitis (Hamid
et al., 1996) and the importance of IL-
13, independent of IL-4 in generation of
Th2 immune response in skin compart-
ment has been described.
In human primary keratinocytes
(KCs), IL-13 interacts with two different
receptors: one is the IL-4 type II
receptor complex (IL-4Ra and IL-
13Ra1) and the other is high-affinity
IL-13Ra2. IL-13Ra1 is expressed on
nearly all cells including KCs except
on T cells and signals via JAK/signal
transducer and activator of transcription
(STAT) pathways (Hershey, 2003). IL-
13Ra2 interacts with IL-13 but not with
IL-4 and has been suggested to function
as a decoy receptor because the cyto-
plasmic region of IL-13Ra2 does not
have a signaling motif or JAK/STAT
binding sequence (Kawakami et al.,
2001). However, it has recently been
suggested that IL-13Ra2 might also be
involved in IL-13 signaling via AP-1
(Fichtner-Feigl et al., 2006). Neverthe-
less, very little is known about the
expression and mechanism regulating
the expression of IL-13Ra1 and IL-
13Ra2 on KCs. With this study, we
examine how cytokines involved in
inflammatory skin diseases can influ-
ence the IL-13 responses of KCs by
modulating the expression of IL-13Ra1
and IL-13Ra2.
To get insight into the cytokine
regulation of IL-13Ra1 expression on
KCs, we analyzed surface expression by
flow cytometry using specific mAbs. In
all experiments, there was a surface
expression of IL-13Ra1 detectable on
KCs (Figure 1a). We used several
cytokines such as transforming growth
factor (TGF)-b1 (0.1–10 ng/ml) and IL-
1b, TNF-a, IFN-g, IL-4, GM-CSF, and IL-
13 at 10 ng/ml to demonstrate the
modulation of IL-13Ra1 on KCs. As
depicted in Figure 1a, TGF-b1 (1 ng/ml)
upregulated the expression of IL-13Ra1
significantly (mean fluorescence inten-
sity7SEM in unstimulated; 10.9371.7
and TGF-b1; 14.7272.4, P¼0.002,
paired t-test, n¼ 7). TGF-b1 at 0.1 and
10 ng/ml concentrations also induced
IL-13Ra1 on KCs significantly (data not
shown). However, IL-1b, TNF-a, GM-
CSF, IL-4, and IFN-g did not show
significant effects on the modulation of
IL-13Ra1 expression (data not shown).
Previously, IFN-g (100 ng/ml) and IL-13
(100 ng/ml) have been described to
upregulate IL-13Ra1 at messenger RNA
level (Wongpiyabovorn et al., 2003). We
could not observe modulation of IL-
Abbreviations: KC, human primary keratinocyte; STAT, signal transducer and activator of transcription;
TGF, transforming growth factor
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